Concepedia

Jeffrey Anderson

JA

Statistics

Publications

23

Citations

7.6K

H-Index

18

Active since

2001

Affiliations

Bristol-Myers Squibb (United States)(Current)

Clinica Universidad de Navarra

University of Hong Kong

Providence Portland Medical Center

Kindai University

Jeffrey Anderson is an author at Bristol-Myers Squibb (United States) specializing in medicine, hepatology, and oncology.

ORCID

Top concepts

Publications per year

2001–2022

23

Publications

23

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.2K citations · Full text

, , +9

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim et al. · JAMA Oncology · 2020 · 1.2K citations · Full text

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Thomas Yau, J.W. Park, Richard S. Finn et al. · Annals of Oncology · 2019 · 639 citations · Full text

, , +9

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis

Thomas Yau, Chiun Hsu, Tae‐You Kim et al. · Journal of Hepatology · 2019 · 267 citations · Full text

A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection

David Gardiner, Jay Lalezari, Eric Lawitz et al. · PLoS ONE · 2013 · 227 citations · Full text

1–5 of 23